Factors associated with TRM in patients with grade II-IV acute GVHD: multiple regression analysis
| Factor . | RR of TRM (95% CI) . | P . |
|---|---|---|
| Number of donors | ||
| One* | 1.0 | |
| Two | 0.4 (0.2-0.9) | .03 |
| Disease | ||
| Other malignant* | 1.0 | |
| Leukemia (CR1,CP1) | 1.7 (0.4-7.0) | .44 |
| Leukemia (other) | 1.9 (0.6-5.9) | .24 |
| Nonmalignant | 3.1 (0.9-10.5) | .07 |
| Disease risk | ||
| Standard* | 1.0 | .52 |
| High | 1.4 (0.5-3.9) | |
| HLA | ||
| 6/6* | 1.0 | |
| 5/6 | 0.4 (0.1-1.5) | .18 |
| 4/6 | 0.4 (0.1-1.4) | .14 |
| Factor . | RR of TRM (95% CI) . | P . |
|---|---|---|
| Number of donors | ||
| One* | 1.0 | |
| Two | 0.4 (0.2-0.9) | .03 |
| Disease | ||
| Other malignant* | 1.0 | |
| Leukemia (CR1,CP1) | 1.7 (0.4-7.0) | .44 |
| Leukemia (other) | 1.9 (0.6-5.9) | .24 |
| Nonmalignant | 3.1 (0.9-10.5) | .07 |
| Disease risk | ||
| Standard* | 1.0 | .52 |
| High | 1.4 (0.5-3.9) | |
| HLA | ||
| 6/6* | 1.0 | |
| 5/6 | 0.4 (0.1-1.5) | .18 |
| 4/6 | 0.4 (0.1-1.4) | .14 |
Reference group.